Rule 3.8A

Appendix 3C

Announcement of buy-back (*except* minimum holding buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/9/99. Origin: Appendix 7B. Amended 13/3/2000, 30/9/2001, 11/01/10

Name of entity	ABN/ARSN
Antisense Therapeutics Limited	41 095 060 745

We (the entity) give ASX the following information.

Information about buy-back

1	Type of buy-back	Off market selective buy back for nil consideration.
2	+Class of shares/units which is the subject of the buy-back *(eg, ordinary/preference)*	Ordinary shares
3	Voting rights *(eg, one for one)*	One for one
4	Fully paid/partly paid *(and if partly paid, details of how much has been paid and how much is outstanding)*	Fully paid
5	Number of shares/units in the +class on issue	176,512,483
6	Whether shareholder/unitholder approval is required for buy-back	Yes, shareholder approval is required and was received on 10 November 2016 at the Company's annual general meeting.
7	Reason for buy-back	The buy-back is part of a Deed of Settlement resulting from the termination of the license Agreement for ATL1103.

+ See chapter 19 for defined terms.

8	Any other information material to a shareholder's/unitholder's decision whether to accept the offer *(eg, details of any proposed takeover bid)*	N/A

On-market buy-back

9	Name of broker who will act on the company's behalf	N/A
10	Deleted 30/9/2001.	
11	If the company/trust intends to buy back a maximum number of shares - that number Note: This requires a figure to be included, not a percentage.	N/A
12	If the company/trust intends to buy back shares/units within a period of time - that period of time; if the company/trust intends that the buy-back be of unlimited duration - that intention	N/A
13	If the company/trust intends to buy back shares/units if conditions are met - those conditions	N/A

Employee share scheme buy-back

14	Number of shares proposed to be bought back	N/A
15	Price to be offered for shares	N/A

+ See chapter 19 for defined terms.

Selective buy-back

16	Name of person or description of class of person whose shares are proposed to be bought back	Strongbridge Biopharma's (formerly Cortendo Cayman) shareholding of 15,025,075 are to be cancelled as part of the Deed of Settlement.
17	Number of shares proposed to be bought back	15,025,075
18	Price to be offered for shares	Nil consideration

Equal access scheme

19	Percentage of shares proposed to be bought back	N/A
20	Total number of shares proposed to be bought back if all offers are accepted	N/A
21	Price to be offered for shares	N/A
22	[+]Record date for participation in offer Cross reference: Appendix 7A, clause 9.	N/A

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

Sign here:  Date: 8 December 2016

(Company secretary)

Print name: Phillip Hains

[+] See chapter 19 for defined terms.